Porcine Reproductive & Respiratory Syndrome (PRRS) around the World – What’s new regarding Global cross‐protection against PRRS - Dr. PH Rathkjen, Boehringer Ingelheim, from the 2016 North American PRRS Symposium, December 3‐4, 2016, Chicago, Illinois, USA. More presentations at http://www.swinecast.com/2016-north-american-prrs-symposium

1. PH Rathkjen
Sr. Global Technical manager PRRS
Boehringer Ingelheim Animal Health GmbH
– What’s new regarding Global
cross-protection against PRRS?
PRRS from around the world

2. From 22 years experience
of heterologous protection against
the economically most important disease
across the globe in19 countries
in Asia, Europe and North America

3. Real world situation
 Low Immunity level + High Pathogen challenge

4. The solution is bigger than the bottle
 Maximize immunity & Minimize exposure

5. What is
important
to
control
PRRSV?
People
are the most
important Gilts
replacement
procedures
are the most
important
Location
is the
most
important What
about
pig
Flow?
You
also need
a good
Immunity
Do we need
to take
PRRSV diversity
Into
Consideration?
Heterologous
Protection!
No matter the virus.
That is what
You
Need!

6. North America:
PRRSV type II
some type I
Most South
America:
Free
Australia:
Free
Eastern Europe: PRRSV
type I (2,3)
Western Europe:
PRRSV type I (1) some
type II
Asia:
PRRSV type II (HP)
some type I
Our basic understanding of PRRSV global distribution

7. Results: Differences between
vaccinated and challenge control
animals were statistically significant
(P<0.05) in all studies.
Conclusion:
 Under the conditions of these
studies, Ingelvac PRRS® MLV
significantly reduced lung lesions
in multiple challenge models which
used genetically diverse
heterologous PRRSV isolates.
Homology
(%)
94%
100%
90%
89%
90%
87%
87%
89%
89%
87%
87%
88%
86%
87%

8. North
America
Europe
Asia
Heterologous protection from
A 22 year old PRRS MLV vaccine
documented globally
China
Guo, IPVS 2008
Fang, APVS 2009
Liu, IPVS 2010
Ao, IPVS 2010
Lin, IPVS 2010
Zhu, IPVS 2011
Yao, APVS 2011
Fang, IPVS 2012
Peng, IPVS 2012
Wei, Vaccine
2013
Lager, Vaccine
2014
Xu IPVS 2016
Tian IPVS 2016
Huang IPVS 2016
Korea
Lee, APVS 2015
Kang, APVS 2015
Seo, APVS 2015
Jung, Vet, Micr. 2016
Lyoo, Virology 2016
Bae, IPVS 2016
Jongyoung, IPVS 2016
Lee, IPVS 2016
Vietnam
Lager, Vaccine 2014
Thailand
Meedacha, APVS 2009
Kongtes, APVS 2011
Krualoy, IPVS 2012
Poommarin, IPVS 2016
Duanghwae, IPVS 2016
Duanghwae , IPVS 2016
Philipines
Manabat, IPVS 2010
Denmark
Nielsen, Vet Micr 1997
Kvisgaard PhD thesis 2013
Kristensen, SEGES 2016
Germany
Pesch, IPVS 2000
Nickoll, IPVS 2002
Medveczkyet, Tier. Um. 2002
Kovacs, 2003
Heller, IPVS 2004
Schröder , IPVS 2004
Schoun , 2007
Hungary
Belgium
USA
Osorio, Leman 1998
Halbur, Leman 1999
Roof, IPVS 2000
Opriessnig, JSHAP 2005
Cano , Vaccine 2007
Zuckerman, Vet Micr 2007
Charerntantanakol, Vet Imm & Imm 2006
Waddell, AASV 2008
Jordan, Leman 2009
Reicks, Leman 2010
Miller, AASV 2011
Garbes,Leman 2011
Linhares, Vaccine 2011
Garbes, AASV 2012
Li, BioMed Res. 2014
Dee, AASV 2014
Patterson, Leman 2013 and AASV 2014
Patterson, Leman 2016
Haiwick, AASV 2016
Haiwick, AASV 2016
Ouyang, Vet Res 2016
Mexico
Angulo, Leman 2007
Diaz, AASV 2011
Diaz IPVS 2012
Centeno, IPVS 2016
Canada
Desrosiers, APVS 2007
Japan
Muehlenthaler, 2012
Kitano, APVS 2015

9. Worldwide documentation
Japanese isolate bs403929 (internal RD data 2012)
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST
AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE
MODEL
USA SDSU-73 2016
USA, 1-7-4- 2016
China HP-PRRS 2013
Korean PRRS isolates 2015

10.  Japanese isolate bs403929
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV
ISOLATE IN A RESPIRATORY CHALLENGE MODEL
internal RD data 2012

11. 28 days
Vaccination
Ingelvac
PRRS® MLV
3 WOA
2 X 20
PRRS neg.
 Japanese isolate bs403929
 EFFICACYOFINGELVACPRRSMLV FORPROTECTIONAGAINSTANASIANPRRSVISOLATEIN A RESPIRATORY
CHALLENGEMODEL
 internal RD data 2012
Blood
Weight
Blood
Weight
Blood
Weight
Blood Blood
14 days
Blood
Design Parameters Results Movinggraphs

12. Design Parameters Results Movinggraphs
Fever (6,7 days vs 3,9 days)
Serum viremia
BAL d 42
0
0.2
0.4
0.6
Diluent MLV
0.56 0.54
0.25
0.44
ADWGkg
ADWG by group and study period
Vaccination period
Challenge period
P=0,0040
0
5
10
15
20
Diluent MLV
Percentconsolidation
Treatment group
Percent pneumonia
Average lung lesion
P=0,0045
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012

13. EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012

14. Design Parameters Results Movinggraphs
EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012

16. Design Parameters Results Movinggraphs
28 days
28 doa
2 X 22
PRRS neg.
Blood Blood BloodBlood Blood
21 days
BloodBlood Blood
0 7 14 21 42353228
Vaccination
Ingelvac
PRRS® MLV

17. Design Parameters Results Movinggraphs
Survival curve
0
20
40
60
80
100 Challenge
d30
d31
d32
d33
d34
d35
d36
d37
d38
d39
d40
d41
d42
d43
d44
d45
d46
d47
d48
Necropsy
Survivalratein%
V/C Non-V/C Strict controls
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a

18. Design Parameters Results Movinggraphs
Percent PCR positive & body temperature
0
10
20
30
40
50
60
70
80
90
100
38.5
39
39.5
40
40.5
41
41.5
challenge d31 d33 d35 d37 d39 d41 d43 d45 d47 Necropsy
%PCRpositives
Bodytemperaturein°C
V/C group -PCR NV/C group - PCR V/C group - temp NV/C group -temp
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a

19. Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a

20. Design Parameters Results Movinggraphs
Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a

21. Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a

22. Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a

24. Design Parameters Results Movinggraphs
Vaccination
Ingelvac
PRRS® MLV 35 days
21 doa
4 X 30
1 x 10
PRRS
neg. Blood Blood BloodBlood Blood
21 days
BloodBlood Blood
d0 7 14 21 45
4
23835
Blood
49
Daily monitoring clinic, temperature d0 – d49
 Strict controls
 2 NV --> chall. Diff.
strains (lineage 1 or 5)
 2 Vax--> chall. Diff.
strains (lineage 1 or 5)

25. Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against

26. Design Parameters Results Movinggraphs
Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against

27. Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against

28. Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against

29. Patterson 2016
Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge, Patterson et al, Leman 2016

30. Design Parameters Results Movinggraphs
28 days
159 PRRSV
Neg
28 DOA
Blood
Weight
Clin
Temp
Blood
Weight
Temp
Clin
Necropsy
Weight Temp
Serum Clin
Blood
Temp
Blood
Temp
14 days
Blood
Temp
Blood, Temp
0 7 14 21 42352928 31
Ingelvac
PRRS® MLV
Group n Treatment
1 45 Ingelvac PRRS® MLV
2 45 Fostera® PRRS
3 65 Placebo

31. Design Parameters Results Movinggraphs
Day 42 Percent Lung Lesions (Median)
asignificantly different from the placebo at P≤0.05
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

32. Design Parameters Results Movinggraphs
Post-challenge ADWG
Group Treatment ADWG in lbs.
1 Ingelvac PRRS® MLV 0.61a
2 Fostera® PRRS 0.49a*
3 Placebo 0.24b
asignificantly different from the placebo at P≤0.05
*different from Ingelvac PRRS® MLV at P≤0.1
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

33. Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

34. Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

35. Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

36. Design Parameters Results Movinggraphs
Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

38. Design Parameters Results Movinggraphs
28 days
90 PRRSV
Neg
21 DOA
Virus
Weight
Clin
Temp
Virus
Weight
Temp
Clin
Necropsy
Weight Temp
Serum Clin
Virus
Temp
Virus
Temp
70 days
Virus
Temp Virus
0 7 14 21 38352928 31
Ingelvac
PRRS® MLV
42 70
Temp daily 14 days,
then weekly
SDSU-73
Group VX Cont Chal
log
1 10 10 4
2 10 10 3
3 10 10 2
4 10 10 1
5 10 no

39. Design Parameters Results Movinggraphs
G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs

40. This study has relevance in the field as
implementation of vaccine in a systematic and
coordinated methodology in a “system-based”
and “area/region-based” program can mitigate
the consequences of PRRSV infection –
subsequently improving health and performance
– and may reduce the level of challenge virus
within and between vaccinated populations
over-time further limiting the consequences of
infection in vaccinated populations
Reid Philips, AASV 2016
Design Parameters Results Movinggraphs
G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs

41. G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs

42. G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs

43. PRRS immunity across the world
Wei, Vaccine 2013
Jeung, Vet, Micr. 2016
Patterson 2016
Muehlenthaler, 2012
Haiwick 2016

44. What’s new on immunological cross-protection
■ Genotype does not predict the level of protection
■ Nothing new!
■ Geography does not predict the level of protection
■ Nothing new!
■ Challenge dose plays an important role in the level of efficacy
■ Reduction of wild type circulation is important

45. Reid Philips Enrique Mondaca Xavier de Paz CarloMaala
RyanHuang OliverDuran JoeVictoria
A.Patterson
G.Haiwick
Thanks to